Amorphous Calcium Carbonate Inhalation Stabilization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current calcium supplements, particularly amorphous calcium carbonate (ACC), face challenges in stability and solubility, making them unsuitable for inhalation, buccal, or sublingual administration due to rapid crystallization and poor bioavailability.
Innovation Solution
Development of ACC compositions stabilized with polyphosphates, bisphosphonates, or phosphorylated amino acids, formulated as dry powders or suspensions for inhalation, buccal, and sublingual administration, ensuring stability and bioavailability through the use of stabilizers like citric acid, pyrophosphate, and triphosphate, which maintain the amorphous form for extended periods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If amorphous calcium carbonate is used as a calcium supplement, then solubility and bioavailability are improved, but stability deteriorates due to rapid crystallization
Solution Approach 1:
The patent introduces stabilizing agents (polyphosphates, proteins, or polysaccharides) as intermediaries that mediate between the amorphous calcium carbonate and the environment. These stabilizers form a protective layer around ACC particles, preventing direct interaction with water and other substances that would trigger crystallization, thereby maintaining stability while preserving bioavailability
Solution Approach 2:
The patent changes the chemical composition parameters by incorporating specific stabilizing agents (polyphosphates at 0.1-10% w/w, proteins at 0.1-10% w/w, or polysaccharides at 0.1-10% w/w) into the ACC formulation. This parameter modification allows the system to maintain the amorphous state for extended periods while retaining the high solubility and bioavailability characteristics of ACC
2Productivity
If amorphous calcium carbonate is administered orally, then calcium supplementation is provided, but effectiveness is insufficient for certain conditions requiring faster or targeted delivery
Solution Approach 1:
The patent develops a universal ACC formulation with stabilizers that can be adapted for multiple administration routes (oral, inhalation, buccal, sublingual). The same stabilized ACC composition serves different therapeutic purposes and delivery methods, making the solution universally applicable across various medical needs and administration preferences
3Duration of action of stationary object
If stabilizers are added to maintain ACC stability, then storage time is extended, but formulation complexity increases
Solution Approach 1:
The patent modifies the formulation by adding stabilizing agents at controlled concentrations (0.1-10% w/w) to extend storage time. This parameter change achieves the goal of prolonged stability while keeping the formulation relatively simple through defined concentration ranges and selection from common stabilizer types
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The stabilized ACC compositions provide effective treatment options for various diseases, including cancer, by ensuring high bioavailability and stability, allowing for efficient delivery through inhalation, buccal, and sublingual routes, with enhanced therapeutic efficacy and prolonged stability.
Implementation Method 1
amorphous calcium carbonate (ACC) stabilized by at least one stabilizer, wherein the ACC is in the form of particles... stabilized by at least one stabilizer... stabilizer is selected from the group consisting of a polyphosphate, bisphosphonate, phosphorylated amino acid, citric acid
Implementation Method 2
Solubility studies suggest dramatic differences between the calcium carbonate polymorphs. While crystalline phases are considered poorly soluble, the amorphous form is much more soluble
Data Source
AI summary
The present invention provides compositions comprising amorphous calcium carbonate (ACC), suitable to being administered by inhalation, and methods for their use in treating ACC-responsive diseases and conditions. Kits for preparing suspension compositions of the present invention are provided as well.